Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0

作者：

Ritchlin, Christopher T. ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Boehncke, Wolf-Henning ^{[4
]}

Tesser, John ^{[5
]}

Chakravarty, Soumya D. ^{[6
,7
]}

Rampakakis, Emmanouil ^{[8
,9
]}

Shawi, May ^{[10
]}

Merola, Joseph F. ^{[11
]}

McInnes, Iain B. ^{[12
]}

Deodhar, Atul ^{[13
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY USA

[2] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA

[3] Univ Washington, Seattle, WA USA

[4] Univ Geneva, Univ Hosp Geneva, Div Dermatol, Geneva, Switzerland

[5] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA

[6] Janssen Sci Affairs LLC, Horsham, PA USA

[7] Drexel Univ, Coll Med, Philadelphia, PA USA

[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[9] JSS Med Res Inc, Montreal, PQ, Canada

[10] Johnson & Johnson, Janssen Pharmaceut Co, Immunol Global Med Affairs, Horsham, PA USA

[11] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol & Immunol, Boston, MA USA

[12] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland

[13] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

42148

引用

页码：AB225 / AB225

页数：1

共 50 条

[21] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
Kameda, Hideto
Hagimori, Kohei
Morisaki, Yoji
Holzkaemper, Thorsten
Konomi, Ayako
Dobashi, Hiroaki
RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1683 - 1703
[22] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
Hideto Kameda
Kohei Hagimori
Yoji Morisaki
Thorsten Holzkämper
Ayako Konomi
Hiroaki Dobashi
Rheumatology and Therapy, 2023, 10 : 1683 - 1703
[23] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
McInnes, I.
Rahman, P.
Gottlieb, A.
Hsia, E.
Kollmeier, A.
Xu, X.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S.
van der Heijde, D.
Mease, P.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
[24] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
Papp, K
Mease, P
Garovoy, M
Zhang, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
[25] Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
Nash, Peter
McInnes, Iain
Ritchlin, Christopher T.
Tam, Lai-Shan
Soriano, Enrique
Starr, Michael
Rampakakis, Emmanouil
Lavie, Frederic
Shawi, May
Baraliakos, Xenofon
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2785 - 2787
[26] LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Gladman, D. D.
Starr, M.
Ranza, R.
Bravo Perdomo, A. M.
Strauss, M.
Shawi, M.
Han, C.
Rampakakis, E.
Ostor, A. Andrew
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1765 - 1765
[27] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana-Maria Bravo
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
[28] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
[29] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
Mease, Philip
van der Heijde, Desiree
Ritchlin, Christopher
Cuchacovich, Rachel
Shuler, Catherine
Lin, Chen-Yen
Vangerow, Harald
Samanta, Suvajit
Lee, Chin
Gladman, Dafna
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[30] LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY
Nash, P.
Mcinnes, I.
Shawi, M.
Nantel, F.
Kollmeier, A.
Rampakakis, E.
Soriano, E.
Gladman, D. D.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1769 - 1770

← 1 2 3 4 5 →